GVS (GVS) Q3 2025 earnings summary

Executive summary

• Healthcare and life science revenues grew 4.8% year-over-year excluding FX and US dialysis, while safety division revenues increased 8.5% year-over-year, both showing strong momentum.

• Adjusted EBITDA margin improved to 24.9%, up 67 basis points year-over-year; adjusted net income rose 7.2% to €36.3 million, with margin increasing to 11.5% from 10.5%.

• Net financial position stood at €271.8 million as of September 2025, with a leverage ratio of 2.5x post-M&A and buyback.

• Consolidated revenues reached €315.6 million for the first nine months of 2025, up 0.2% at constant exchange rates year-over-year.

Financial highlights

• Adjusted EBITDA was €78.7 million, up 0.8% year-over-year, with margin improving to 24.9%.

• Adjusted net income as a percentage of revenues increased to 11.5% from 10.5% year-over-year.

• Ordinary cash generation in nine months was €13 million, despite a €20 million negative working capital trend, expected to recover in Q4.

• Cash and cash equivalents at period end were €55.5 million, down from €102.9 million at year-end 2024.

• Net financial debt increased to €271.8 million from €219.8 million at December 31, 2024.

Outlook and guidance

• FY 2025 guidance projects low single-digit sales growth excluding FX versus FY 2024, with adjusted EBITDA margin expected to improve by 100-150 basis points.

• Leverage ratio projected around 2.2x at year-end 2025, including buyback impact.

• FY 2026 outlook anticipates new product launches in medtech and safety, ramp-up in transfusion medicine, and growth in life science and mobility, especially electric vehicles and hydrogen membrane products.